Meta AnalysisID 1553
改良二联疗法与含铋剂四联疗法根除幽门螺杆菌的疗效比较
CRD42019129064
How does modified dual therapy for Helicobacter pylori eradication compared to bismuth quadruple therapy?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 1553
- Evidence Id
- 10111
- Core Evidence Id
- 10111
- Source Meta Analysis Id
- 1508
- Herb2 Meta Analysis Id
- HBMA001508
- Crd Id
- CRD42019129064
- Title
- Eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy for helicobacter pylori
- Review Question
- How does modified dual therapy for Helicobacter pylori eradication compared to bismuth quadruple therapy?
- Study Type Included
- We will include RCTs to assess the eradication therapy and side effect.
- Condition Being Studied
- Helicobacter pylori, high dose dual therapy, eradication rate.
- Participant
- Inclusion: Adults diagnosed H pylori infection (as diagnosed using any recognised diagnostic criteria), regardless of gender, age, or race; treat with modified dual therapy and bismuth-containing quadruple therapy. Exclusion: Adolescents (under 18 years of age) or the treatments were not modified dual therapy and bismuth-containing quadruple therapy.
- Animal
- Human Disease Modelled
- Intervention
- Helicobacter pylori infection can cause many gastrointestinal diseases, including peptic ulcers, chronic active gastritis, gastric mucosa-associated lymphoid tissue lymphoma, and ultimately deadly gastric adenocarcinoma. And the Bismuth-containing quadruple therapy has been highly recommended as eradiction treatment.Several clinical trials reported the H pylori eradication rates of themodified dual therapy compared with bismuthcontaining quadruple therapy. The 14-day modified dual therapy group: esomeprazole was administrated 4 times daily, 30 minutes before 3 meals and 1 hour before sleep; amoxicillin was administered 30 minutes after 3 meals and 1 hour before sleep.
- Comparator Control
- The bismuth containing quadruple therapy group (standard therapy): the quadruple therapy was administered twice daily at approximately 12-hour intervals. Esomeprazole and bismuth potassium citrate were administered 30 minutes before breakfast and dinner; amoxicillin and clarithromycin were administered 30 minutes after breakfast and dinner.
- Main Outcome
- H. pylori eradication rates Measures of effect The primary outcome was efficacy of H. pylori eradication rates of modified dual therapy compared with bismuthcontaining quadruple therapy. A cut-off value greater than 2.4 defined H. pylori patients and indicated failure of the eradication therapy.
- Outcome Measure
- Additional Outcome
- Adherence; side effect; the cost; antibiotic resistance tests. Measures of effect (1) medication adherence:medication possession ratio (MRP) was defined as the proportion of days within the fixed 14-day treatment that a patient had access to the medication; (2) side effect: were reported by participants as instructed according to the influence on their daily activities; (3) the cost; (4) Antibiotic resistance tests.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Antacids; Antidiarrheals; Bismuth; Helicobacter pylori; Humans
- Contact
- Zhenghe Liu [email protected]
- Organisational Affiliation
- Luohe Central Hospital, Luohe City, Henan Province
- Funding Source
- Luohe Central Hospital, Luohe City, Henan Province
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2019-04-09
- Registration Date
- 2019-07-12
- Anticipated Start Date
- 2019-03-20
- Anticipated Completion Date
- 2019-05-30
- Title Cn
- 改良二联疗法与含铋剂四联疗法根除幽门螺杆菌的疗效比较
- Title En
- Eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy for helicobacter pylori
- Bilingual Status
- complete